191 related articles for article (PubMed ID: 7507654)
1. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
Teicher BA; Holden SA; Ara G; Northey D
Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Teicher BA; Sotomayor EA; Huang ZD
Cancer Res; 1992 Dec; 52(23):6702-4. PubMed ID: 1384969
[TBL] [Abstract][Full Text] [Related]
3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
4. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
[TBL] [Abstract][Full Text] [Related]
6. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D
Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911
[TBL] [Abstract][Full Text] [Related]
7. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
8. Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcoma.
Herman TS; Teicher BA
Cancer Res; 1988 May; 48(10):2693-7. PubMed ID: 3359430
[TBL] [Abstract][Full Text] [Related]
9. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
Teicher BA; Holden SA; al-Achi A; Herman TS
Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
[TBL] [Abstract][Full Text] [Related]
10. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
[TBL] [Abstract][Full Text] [Related]
11. Combination of etanidazole with cyclophosphamide and platinum complexes.
Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
[TBL] [Abstract][Full Text] [Related]
12. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
14. Effects of stem cell factor on the growth and radiation survival of tumor cells.
Shui C; Khan WB; Leigh BR; Turner AM; Wilder RB; Knox SJ
Cancer Res; 1995 Aug; 55(15):3431-7. PubMed ID: 7542170
[TBL] [Abstract][Full Text] [Related]
15. Combined interleukin-1 beta/interleukin-6 treatment in mice: synergistic myelostimulatory activity and myelorestorative effect after cyclophosphamide-induced myelosuppression.
Tritarelli E; Greco G; Testa U; Belardelli F; Peschle C; Proietti E
Cancer Res; 1994 Dec; 54(24):6469-76. PubMed ID: 7987845
[TBL] [Abstract][Full Text] [Related]
16. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
[TBL] [Abstract][Full Text] [Related]
17. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.
Teicher BA; Crawford JM; Holden SA; Cathcart KN
Cancer Res; 1987 Oct; 47(19):5036-41. PubMed ID: 3113727
[TBL] [Abstract][Full Text] [Related]
18. Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloroplatinum(II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma.
Herman TS; Teicher BA; Holden SA; Pfeffer MR; Jones SM
Cancer Res; 1990 May; 50(9):2734-40. PubMed ID: 2139359
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy to a primary tumor accelerates metastatic growth in mice.
Camphausen K; Moses MA; Beecken WD; Khan MK; Folkman J; O'Reilly MS
Cancer Res; 2001 Mar; 61(5):2207-11. PubMed ID: 11280788
[TBL] [Abstract][Full Text] [Related]
20. Gamma-ray-induced cell killing and chromosome abnormalities in the bone marrow of p53-deficient mice.
Wang L; Cui Y; Lord BI; Roberts SA; Potten CS; Hendry JH; Scott D
Radiat Res; 1996 Sep; 146(3):259-66. PubMed ID: 8752303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
